D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 100 Citations 50,275 573 World Ranking 3777 National Ranking 2156

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Gene

His scientific interests lie mostly in Renal cell carcinoma, Internal medicine, Sunitinib, Carcinoma and Oncology. His Renal cell carcinoma study incorporates themes from Survival rate, Targeted therapy and Clinical endpoint. As part of his studies on Internal medicine, Brian I. Rini frequently links adjacent subjects like Surgery.

His study in Sunitinib is interdisciplinary in nature, drawing from both Cancer research, Urology, Vascular endothelial growth factor, Tyrosine-kinase inhibitor and Immunotherapy. The various areas that Brian I. Rini examines in his Carcinoma study include Gastroenterology, Clear cell renal cell carcinoma, Retrospective cohort study, Nephrectomy and Survival analysis. The concepts of his Oncology study are interwoven with issues in Nivolumab, Pharmacology and Cohort.

His most cited work include:

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (1476 citations)
  • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial (1320 citations)
  • Sunitinib in Patients With Metastatic Renal Cell Carcinoma (1089 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Renal cell carcinoma, Internal medicine, Oncology, Sunitinib and Surgery. His Renal cell carcinoma research integrates issues from Targeted therapy and Carcinoma. In the subject of general Internal medicine, his work in Cancer, Nivolumab, Clinical trial and Bevacizumab is often linked to In patient, thereby combining diverse domains of study.

His Oncology study combines topics in areas such as Immunotherapy, Vascular endothelial growth factor, Phases of clinical research and Hazard ratio. His studies deal with areas such as Cancer research, Temsirolimus, Tyrosine-kinase inhibitor and Urology as well as Sunitinib. His work on Clinical endpoint as part of general Surgery study is frequently linked to Response Evaluation Criteria in Solid Tumors, bridging the gap between disciplines.

He most often published in these fields:

  • Renal cell carcinoma (64.57%)
  • Internal medicine (59.10%)
  • Oncology (49.86%)

What were the highlights of his more recent work (between 2018-2021)?

  • Renal cell carcinoma (64.57%)
  • Internal medicine (59.10%)
  • Oncology (49.86%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Renal cell carcinoma, Internal medicine, Oncology, Sunitinib and Cancer research. Brian I. Rini works in the field of Renal cell carcinoma, focusing on Axitinib in particular. Internal medicine is a component of his Nivolumab, Ipilimumab, Cancer, Clinical trial and Randomized controlled trial studies.

When carried out as part of a general Oncology research project, his work on Overall survival, Kidney cancer and Tivozanib is frequently linked to work in In patient, therefore connecting diverse disciplines of study. His study in Sunitinib is interdisciplinary in nature, drawing from both Atezolizumab, First line, Post-hoc analysis, Bevacizumab and Subgroup analysis. His research in Cancer research tackles topics such as Clear cell renal cell carcinoma which are related to areas like Clear cell.

Between 2018 and 2021, his most popular works were:

  • Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma (836 citations)
  • Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma (692 citations)
  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. (468 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

His primary areas of study are Renal cell carcinoma, Internal medicine, Oncology, Sunitinib and Ipilimumab. The study incorporates disciplines such as Clinical trial, Angiogenesis, PD-L1, Targeted therapy and Carcinoma in addition to Renal cell carcinoma. His work on Randomized controlled trial, Kidney cancer, Clinical endpoint and Cohort study is typically connected to Hydroxychloroquine as part of general Internal medicine study, connecting several disciplines of science.

He combines subjects such as Survival rate and Adverse effect with his study of Oncology. His work carried out in the field of Sunitinib brings together such families of science as Urology, Atezolizumab, Subgroup analysis and Hazard ratio. The various areas that Brian I. Rini examines in his Ipilimumab study include Nivolumab, Checkmate and VEGF receptors.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Renal Cell Carcinoma

Brian I Rini;Steven C Campbell;Bernard Escudier.
(2009)

2466 Citations

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera.
The New England Journal of Medicine (2018)

1937 Citations

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

Brian I. Rini;Bernard Escudier;Piotr Tomczak;Andrey Kaprin.
The Lancet (2011)

1851 Citations

Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer;Brian I. Rini;Brian I. Rini;Ronald M. Bukowski;Brendan D. Curti.
JAMA (2006)

1528 Citations

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Brian I Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler.
Journal of Clinical Oncology (2008)

1070 Citations

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini;Elizabeth R. Plimack;Viktor Stus;Rustem Gafanov.
The New England Journal of Medicine (2019)

1066 Citations

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

Brian I. Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler.
Journal of Clinical Oncology (2010)

922 Citations

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

Robert J. Motzer;Brian I. Rini;David F. McDermott;Bruce G. Redman.
Journal of Clinical Oncology (2015)

918 Citations

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini.
The New England Journal of Medicine (2019)

914 Citations

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Toni K. Choueiri;Bernard Escudier;Thomas Powles;Paul N. Mainwaring.
The New England Journal of Medicine (2015)

880 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Brian I. Rini

Toni K. Choueiri

Toni K. Choueiri

Harvard University

Publications: 234

Bernard Escudier

Bernard Escudier

Institut Gustave Roussy

Publications: 191

Robert J. Motzer

Robert J. Motzer

Memorial Sloan Kettering Cancer Center

Publications: 167

Thomas Powles

Thomas Powles

Queen Mary University of London

Publications: 116

David F. McDermott

David F. McDermott

Beth Israel Deaconess Medical Center

Publications: 101

Nizar M. Tannir

Nizar M. Tannir

The University of Texas MD Anderson Cancer Center

Publications: 101

Alain Ravaud

Alain Ravaud

University of Bordeaux

Publications: 100

Christopher G. Wood

Christopher G. Wood

The University of Texas MD Anderson Cancer Center

Publications: 89

James Larkin

James Larkin

Royal Marsden NHS Foundation Trust

Publications: 89

Sabina Signoretti

Sabina Signoretti

Brigham and Women's Hospital

Publications: 84

Joaquim Bellmunt

Joaquim Bellmunt

Beth Israel Deaconess Medical Center

Publications: 83

Thomas E. Hutson

Thomas E. Hutson

Texas Oncology

Publications: 73

Rodolfo Montironi

Rodolfo Montironi

Marche Polytechnic University

Publications: 72

Shahrokh F. Shariat

Shahrokh F. Shariat

Medical University of Vienna

Publications: 71

Robert A. Figlin

Robert A. Figlin

University of California, Los Angeles

Publications: 68

Liang Cheng

Liang Cheng

Indiana University

Publications: 65

Something went wrong. Please try again later.